Denosumab Use in Patients with Chronic Kidney Disease

Introduction to Denosumab in CKD

The American College of Physicians recommends denosumab as a first-line treatment option for patients with CKD stages 3a-5 who have low bone mineral density and/or fragility fractures, primarily because it does not require dose adjustment for renal function 1

Before initiating denosumab in patients with eGFR <30 mL/min/1.73 m², evaluation for CKD-mineral and bone disorder (CKD-MBD) by measuring intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25(OH)₂ vitamin D is required 1
Treatment decisions must account for the magnitude and reversibility of biochemical abnormalities (calcium, phosphate, PTH) 2, 3
Bone biopsy should be considered to accurately diagnose the underlying bone phenotype, as antiresorptives like denosumab can exacerbate low bone turnover states 2, 3

Use of denosumab in males with CKD stages 4-5D is considered off-label 4
Denosumab is conditionally recommended against in solid organ transplant recipients due to cardiovascular risks (myocardial infarction, stroke, death) 4

All patients receiving denosumab must take calcium 1000 mg daily and vitamin D at least 400 IU daily 1
For patients with eGFR <30 mL/min/1.73 m², biologically active vitamin D (calcitriol, paricalcitol, or doxercalciferol) may be required instead of vitamin D₃ or D₂ 1

Intensive monitoring is essential, particularly in advanced CKD, with serum calcium and phosphorus checked at least monthly for the first 3 months, then every 3 months thereafter 1
PTH levels should be monitored at least every 3 months for the first 6 months, then every 3 months 1